Evropska unija - slovenščina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - virus varicella-zoster (v živo, oslabljen) - herpes zoster; immunization - virusna cepiva - zdravilo zostavax je indicirano za preprečevanje herpes zoster ("zoster" ali pasovec) in posterpetične nevralgije povezane s herpes-zosterom. zostavax je označen za imunizacijo posameznikov 50 let ali starejši.

Evropska unija - slovenščina - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - cepiva - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. uporaba shingrix mora biti v skladu z uradnimi priporočili.

Evropska unija - slovenščina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - virus, živi oslabljeni, ošpice, virus, živi oslabljeni, mumps, virus, živi oslabljeni, rdečkam, virus, živi oslabljen, noric - chickenpox; rubella; measles; mumps; immunization - cepiva - zdravilo proquad je indicirano za sočasno cepljenje proti ošpicam, mumpsu, rdečkam in noricam pri osebah, starih od 12 mesecev. proquad se lahko upravljajo posamezniki iz 9 mesecev starosti v posebnih okoliščinah (e. tako , da so skladni z nacionalnimi cepljenje urnike, izbruh situacijah, ali potovanje v regiji z visoko razširjenost ošpicam.

Evropska unija - slovenščina - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - zavrnitev presadka - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - fingolimod hidroklorid - multiplo sklerozo, recidivno-nakazila - imunosupresivi, selektivno imunosupresivi - navedeno kot eno bolezen spreminjanje terapije v zelo aktivna recidivno nakazila multiplo sklerozo, za naslednje skupine odraslih bolnikov in pediatričnih bolnikih, starih 10 let in več:bolniki z zelo aktivna bolezen kljub popolno in ustrezno tečaj zdravljenja z vsaj eno bolezen spreminjanje therapyorpatients s hitro razvijajočimi se hudo recidivno nakazila multiplo sklerozo, opredeljeno z 2 ali več onemogočanje zagonov v enem letu, in z 1 ali več gadolinium krepitev poškodbe na možganih, mri ali znatno povečanje t2 lezije obremenitvi, kot je v primerjavi s predhodnim zadnjih mri.

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm limited  - siponimod fumaric acid - multiplo sklerozo, recidivno-nakazila - selektivni imunosupresivi - mayzent je indiciran za zdravljenje odraslih bolnikov s sekundarno progresivno multiplo sklerozo (spms), ki imajo aktivno bolezen, dokazuje zagonov ali slikovne funkcije vnetne aktivnosti.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi belgium - alemtuzumab - multiple skleroza - selektivni imunosupresivi - lemtrada je indicirano za odraslih bolnikov z recidivno-remitentno multiple skleroze (rrms) z aktivno boleznijo določi kliničnih ali slikanje funkcije.

Evropska unija - slovenščina - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multiple skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Evropska unija - slovenščina - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, črevesne protivnetna / antiinfective agenti - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.